OTEZLAs novel mechanism of action and oral administration provides psoriatic arthritis patients with a much needed treatment option. Celgene will continue our dedication to develop and deliver innovative medicines for people affected by diseases where there is a high unmet need. OTEZLA is an oral treatment for psoriatic arthritis that works by reducing the activity of an enzyme called phosphodiesterase 4 (PDE4), which is involved in the process of inflammation.8 By reducing the activity of this enzyme, OTEZLA can help to control the inflammation associated with psoriatic arthritis, and thereby reduce the signs and symptoms of the condition.9, 10 The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) programme is one of the largest global clinical development programmes ever conducted in psoriatic arthritis and it measured the efficacy and safety of OTEZLA.11 Across PALACE 1, 2 and 3, significantly more patients on OTEZLA achieved ACR20 at Week 16 than those on placebo.8 OTEZLA has demonstrated proven and durable efficacy in psoriatic arthritis, with improvement in swollen and tender joints, as well as pre-existing dactylitis (inflammation of fingers and toes, commonly known as sausage fingers and toes) and enthesitis (inflammation at sites where tendons or ligaments insert into bone) with a statistically significant improvement in physical function.8 The most common adverse reactions in Phase III clinical studies were diarrhoea and nausea. These adverse reactions generally occurred within the first two weeks of treatment and usually resolved within four weeks.2 Ends NOTES TO EDITORS About OTEZLA OTEZLA is an oral inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP).8 PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators.9,10 OTEZLA, alone or in combination with Disease Modifying Anti-Rheumatic Drugs (DMARDs), was approved by the European Medicines Agency in 2015 for the treatment of psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. OTEZLA was also licensed by the European Commission for the treatment of moderate to severe chronic plaque psoriasis in adult patients who do not respond to, have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).8 Read More OTEZLA has a novel mechanism of action, offering a treatment option that does not require pre-screening for tuberculosis or regular laboratory tests.2 In clinical trials of psoriatic arthritis, treatment with OTEZLA demonstrated a statistically significant improvement in physical function vs. placebo as well as improving disease-related quality of life.12 The Summary of Product Characteristics is available here . About Psoriatic Arthritis Psoriatic arthritis is a painful, chronic inflammatory disease characterised by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and decrease in physical functioning.13 Psoriatic arthritis can impact the ability to perform day-to-day activities and has been reported to increase work disability.14,15 Enthesitis (inflammation at sites where tendons or ligaments insert into bone) and dactylitis (inflammation of fingers and toes, commonly known as sausage digits) are specific disease manifestations related to psoriatic arthritis.13 Up to 30% of people with psoriasis may also experience psoriatic arthritis.16 About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene UK & Ireland is a subsidiary of Celgene Corporation. For more information, please visit FollowCelgeneon Social Media: @Celgene , Pinterest , LinkedIn and YouTube . REFERENCES 1 NICE: Apremilast for the treatment of active psoriatic arthritis 2 Reich K et al.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/oral-otezla-apremilast-receives-positive-091900634.html
Paul Rivett , President of Fairfax, will be appointed as a director of Mosaic at closing of the Fairfax Financing which is expected to occur in late January 2017 . “We are excited to partner with John Mackay , Harold Kunik and Mark Gardhouse and their team through a direct investment in Mosaic” said Paul Rivett , President of Fairfax. “John and Harold have a long track record of successfully applying value investing principles to acquire majority positions in strong cash flow producing small and medium sized businesses. They have been successfully applying a decentralized approach that ensures the management remains invested and operating on a day-to-day basis. Over time, some of these investments are expected to grow to a size where they may need additional capital from Fairfax. Fairfax often receives opportunities that are difficult to act on because of their smaller size which may be of interest to Mosaic. We look forward to having a partner whose expertise and experience in mid-market private equity acquisitions over the last decade can be combined with our flow of opportunities.” John Mackay , Executive Chairman of Mosaic, added “It is great to have a partner that shares our long term, value oriented approach to investing. We also expect to benefit from the vast experience and investment knowledge of Prem Watsa , Fairfax’s Chairman, and the entire team at Fairfax.” “We are very pleased to have Fairfax as a key partner in our business,” said Mark Gardhouse CEO of Mosaic. “Fairfax is one of the best capital allocators in North America and we look forward to working with them. Fairfax is providing Mosaic with a significantly reduced cost of capital which positively impacts our sustainable cash flow. check thisThe Preferred Securities will be delisted from the TSX Venture Exchange.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/fairfax-financial-invest-150-million-003500441.html
The skin becomes scaly and looks similar to that seen in case of psoriasis. The course of treatment for scoliosis depends on a number of factors: Type and cause of the disorder Degree, pattern, size and location of the curve In mild cases of scoliosis a treatment is not required. If you suffer from any symptoms of gout, you should consult the doctor and make changes in the diet according to his recommendations. In women, the disease is known to affect other joints of the body like, shoulders, hips, feet, etc. read the full info hereWhen the body does not produce enough platelets, or those that are produced don’t function well, it could cause bruising. It is important to note that mild elevation in body temperature can also be caused due to environmental factors, as well as rigorous physical activity. The first and most important skill, or rather quality required is the love for children. The problem with perceiving these seemingly harmless bruises is that one tends to ignore them as a common occurrence and resorts to merely administering bruise treatment to it. Aortitis, apical lung fibrosis and ectasia are some less common symptoms. Next, you will have to deal with paranoid parents in this profession.